Comparing two low-dose preventives for severe hemophilia a
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial compares two low-dose medicines to prevent bleeding episodes in people with severe hemophilia A: a newer medicine (emicizumab) versus the standard factor VIII treatment. It may help find a more convenient or effective way to reduce bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a severe form of the bleeding disorder hemophilia A.
- You can have hemophilia A with or without inhibitors (antibodies that block factor VIII treatment).
- You are willing to take part in the study and follow its schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
This study tests a medicine called emicizumab, given as a shot under the skin, to see how well it works in children with hemophilia A. It may help prevent bleeding episodes and improve quality of life.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This study tests a new medicine called SR604, given as a shot under the skin, to help prevent bleeding in people with hemophilia A or B. If it works, it could reduce the number of bleeding episodes and make daily life easier.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.